Evidence map›Paper›PMID 40693740›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Impact of Repeated Non-Fatal Infections on Quality of Life and Graft Function in ABO-Incompatible Kidney Transplants.

Federica Bocchi, Isabelle Binet, Dela Golshayan, Fadi Haidar, Cédric Hirzel, Thomas Müller, Thomas Schachtner, Daniel Sidler

Abstract read
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Impact of Repeated Non-Fatal Infections on Quality of Life and Graft Function in ABO-Incompatible Kidney Transplants.Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Federica BocchiDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland.ORCID https://orcid.org/0000-0003-4198-1645
Isabelle BinetClinic of Nephrology, Transplantation Medicine, Kantonspital St. Gallen, St. Gallen, Switzerland.
Dela GolshayanTransplantation Center, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.ORCID https://orcid.org/0000-0001-5631-6096
Fadi HaidarDepartment of Nephrology and Hypertension, HUG, Geneva University Hospital, Geneva, Switzerland.
Cédric HirzelDepartment of Infectious Diseases, Inselspital, Bern University Hospital, Bern, Switzerland.ORCID https://orcid.org/0000-0002-7870-912X
Thomas MüllerDepartment of Nephrology, USZ, Zurich University Hospital, Zurich, Switzerland.
Thomas SchachtnerDepartment of Nephrology, USZ, Zurich University Hospital, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-5549-4798
Daniel SidlerDepartment of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, Switzerland.ORCID https://orcid.org/0000-0002-2435-5936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney transplantation (KT) is the preferred treatment for kidney failure, with living donor KT (LDKT) offering better outcomes and improved quality of life (QOL) than deceased donor KT. ABO incompatibility (ABOi) once restricted LDKT, but desensitization protocols now enable ABOi LDKT, expanding the donor pool with favorable outcomes. However, added risks of ABOi remain debated. We examined the impact of repeated infections on graft loss and death in both ABO-compatible (ABOc) and ABOi LDKT recipients.

methodsRetrospective, nationwide Swiss Transplant Cohort Study from May 2008 to December 2022, including all ABOi LDKT patients. Clinically relevant infections (viral, bacterial, fungal, and parasitic) were analyzed as repeated adverse events.

resultsAmong 227 ABOi LDKT and 1172 ABOc recipients, 13% (183/1399) had ≥ 2 significant infections within the first 6 months. ABOi was independently associated to a higher infection risk (HR 1.21, 95% CI 1.10-1.34, p < 0.001). Patients with early recurrent infections were older, often female, and had ABOi LDKT. Patients with ≥ 2 infections faced increased risks of graft loss, lower eGFR, and reduced QOL.

conclusionABOi LDKT patients face a higher risk of recurrent infections, especially within 6 months post-KT, associated with reduced allograft function and lower QOL.

Indexed as

ABO Blood-Group SystemBlood Group IncompatibilityGraft RejectionInfectionsKidney TransplantationQuality of LifeAdultAgedFemaleGraft SurvivalHumansLiving DonorsMaleMiddle AgedRetrospective StudiesRisk FactorsABO Blood-Group SystemABO incompatibleimmunoadsorptioninfectionskidney transplantationrepeated events

Identifiers

PMID40693740
PMCPMC12519917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.